ClinicalTrials.gg
CompletedNCT05362045Updated Nov 21, 2022

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

A Phase 1 interventional study of Mavacamten in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-21.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Enrollment
4th of 21
158 · median 75
Started
2022
with 3 others
Phase 1
5 of 21
none open now
Registered
11th of 21
by date
Lead sponsor
10 of 21
Bristol-Myers Squibb

Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 4th largest by enrollment, is one of 4 that started in 2022, is one of 5 in phase 1, and was the 11th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects on the single-dose drug levels of mavacamten in healthy participants.

03

Conditions studied

  • Healthy Participants

Keywords

  • Mavacamten
  • Healthy Participants
  • Bioequivalence
  • Hypertrophic Cardiomyopathy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18 and 32 kg/m\^2, inclusive, at the Screening Visit
  • Healthy, as determined by physical examination, vital signs, (ECGs), and clinical laboratory assessments within the normal range at the screening visit and/or on Day -1

Exclusion criteria

Exclusion Criteria:

  • Current or recent (within 3 months of study intervention administration) gastrointestinal disease
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    Mavacamten- Dose A

    Drug: Mavacamten

  • Experimental
    Mavacamten- Dose B

    Drug: Mavacamten

Interventions

  • Specified dose on specified days

    Also known as: BMS-986427, MYK-461

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to approximately 1 month

  2. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration ((AUC(0-T))

    Time frame: Up to approximately 1 month

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time ((AUC(INF))

    Time frame: Up to approximately 1 month

Secondary outcomes

  1. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to approximately 1 month

  2. Terminal half-life (T-HALF)

    Time frame: Up to approximately 1 month

  3. Number of participants with adverse events (AEs)

    Time frame: Up to approximately 1 month

  4. Number of participants with serious adverse events (SAEs)

    Time frame: Up to approximately 1 month

  5. Number of participants with vital sign abnormalities exceeding predefined thresholds

    Time frame: Up to approximately 1 month

  6. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to approximately 1 month

  7. Number of participants with physical exam abnormalities

    Time frame: Up to approximately 1 month

  8. Number of participants with clinical laboratory evaluation abnormalities

    Time frame: Up to approximately 1 month

07

Study locations

4 sites
  • Clinical pharmacology of Miami
    Miami, Florida 33014, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • QPS Springfield
    Springfield, Missouri 65802, United States
  • Ppd Phase I Clinic
    Austin, Texas 78744, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Aug 2022, 3 months.

Of 12 phase 1 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2022
First posted
May 5, 2022
StartActual
May 16, 2022
Primary completionActual
Aug 19, 2022
CompletionActual
Aug 19, 2022
Last update
Nov 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05362045
Responsible party
Sponsor
First posted
May 5, 2022
Start date
May 16, 2022
Primary completion
Aug 19, 2022
Completion
Aug 19, 2022
Last update
Nov 21, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion